Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study

Basit Öğe Kaydı
dc.contributor.authorDemirci, Ayse
dc.contributor.authorAlkis, Necati
dc.contributor.authorDane, Faysal
dc.contributor.authorDurnali, Ayse
dc.contributor.authorYazici, Omer Kamil
dc.contributor.authorRzayev, Rashad
dc.contributor.authorKaya, Serap
dc.date.accessioned2024-04-24T17:11:25Z
dc.date.available2024-04-24T17:11:25Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractAimThe goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. MethodsDemographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. ResultsThe median duration of GnRH analogues use was 2213.6 (range, 1-87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4-12 months (Group A), 13-24 months (Group B) and 25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 +/- 30.3 (range, 4-188) months. The OS in patients 35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). ConclusionThere is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use.en_US
dc.identifier.doi10.1111/ajco.12685
dc.identifier.endpageE151en_US
dc.identifier.issn1743-7555
dc.identifier.issn1743-7563
dc.identifier.issue2en_US
dc.identifier.pmid28429422
dc.identifier.scopus2-s2.0-85018574265
dc.identifier.scopusqualityQ3
dc.identifier.startpageE145en_US
dc.identifier.urihttps://doi.org/10.1111/ajco.12685
dc.identifier.urihttps://hdl.handle.net/11468/17491
dc.identifier.volume14en_US
dc.identifier.wosWOS:000427463600021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectMedical Oncologyen_US
dc.subjectPharmacyen_US
dc.titleRetrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) studyen_US
dc.titleRetrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu